- 1 Genomic epidemiology of the rotavirus G2P[4] strains in coastal Kenya pre- and post-
2 rotavirus vaccine introduction, $2012 2018$
- 2 rotavirus vaccine introduction, $2012 2018$
-

35 ABSTRACT
36 The introduct

36 The introduction of rotavirus vaccines into the national immunization programme in many
37 countries has led to a decline of childhood diarrhoea disease burden. Coincidentally, the 37 countries has led to a decline of childhood diarrhoea disease burden. Coincidentally, the
38 incidence of some rotavirus group A (RVA) genotypes, has increased, which may result from 38 incidence of some rotavirus group A (RVA) genotypes, has increased, which may result from
39 non-vaccine-type replacement. Here we investigate the evolutionary genomics of rotavirus 39 non-vaccine-type replacement. Here we investigate the evolutionary genomics of rotavirus
40 G2PI41 which has shown an increase in countries that introduced the monovalent Rotarix® 40 G2P[4] which has shown an increase in countries that introduced the monovalent Rotarix[®]
41 vaccine. We examined the 63 RVA G2P[4] strains sampled from children (aged below 13 41 vaccine. We examined the 63 RVA G2P[4] strains sampled from children (aged below 13
42 vears) admitted to Kilifi County Hospital. Coastal Kenva. pre- (2012 to June 2014) and post-942 years) admitted to Kilifi County Hospital, Coastal Kenya, pre- (2012 to June 2014) and post-
43 (July 2014-2018) rotavirus vaccine introduction. All the 63 genome sequences showed a 43 (July 2014-2018) rotavirus vaccine introduction. All the 63 genome sequences showed a
44 typical DS-1 like genome constellation G2-PI41-I2-R2-C2-M2-A2-N2-T2-E2-H2. G2 sub-44 typical DS-1 like genome constellation G2-P[4]-I2-R2-C2-M2-A2-N2-T2-E2-H2. G2 sub-
45 lineage IVa-3 strains predominated in the pre-vaccine era co-circulating with low numbers of 45 lineage IVa-3 strains predominated in the pre-vaccine era co-circulating with low numbers of
46 G2 sub-lineage IVa-1 strains, whereas sub-lineage IVa-3 strains dominated the post-vaccine 46 G2 sub-lineage IVa-1 strains, whereas sub-lineage IVa-3 strains dominated the post-vaccine
47 period. In addition, in the pre-vaccine period, P[4] sub-lineage IVa strains co-circulated with 47 period. In addition, in the pre-vaccine period, P[4] sub-lineage IVa strains co-circulated with
48 low numbers of P[4] lineage II strains, but P[4] sub-lineage IVa strains predominated in the 48 low numbers of P[4] lineage II strains, but P[4] sub-lineage IVa strains predominated in the post-vaccine period. On the global phylogeny, the Kenyan pre- and post-vaccine G2P[4] 49 post-vaccine period. On the global phylogeny, the Kenyan pre- and post-vaccine G2P[4]
50 strains clustered senarately suggesting that different virus populations circulated in the two 50 strains clustered separately, suggesting that different virus populations circulated in the two
51 periods. However, the strains from both periods exhibited conserved amino acid changes in 51 periods. However, the strains from both periods exhibited conserved amino acid changes in
52 the known antigenic epitones suggesting that replacement of the predominant G2PI41 cluster 52 the known antigenic epitopes, suggesting that replacement of the predominant G2P[4] cluster
53 was unlikely a result of immune escape. Our findings demonstrate that the pre- and post-53 was unlikely a result of immune escape. Our findings demonstrate that the pre- and post-
54 vaccine G2PI41 strains circulating in Kilifi. coastal Kenva. differed genetically, but likely 54 vaccine G2P[4] strains circulating in Kilifi, coastal Kenya, differed genetically, but likely
55 vere antigenically similar. This information informs the discussion on the consequences of 55 were antigenically similar. This information informs the discussion on the consequences of
56 rotavirus vaccination on rotavirus diversity. 56 rotavirus vaccination on rotavirus diversity.
57

59 INTRODUCTION
60 In 2009, the V

60 In 2009, the World Health Organization (WHO) recommended inclusion of rotavirus
61 vaccines into the national immunization programmes (NIPs) globally [1]. Kenya introduced 61 vaccines into the national immunization programmes (NIPs) globally [1]. Kenya introduced
62 the WHO pre-qualified Rotarix® RVA (rotavirus group A) vaccine into its NIP in July 2014 62 the WHO pre-qualified Rotarix® RVA (rotavirus group A) vaccine into its NIP in July 2014
63 [2]. With the increasing uptake of rotavirus vaccines globally, there has been a significant 63 [2]. With the increasing uptake of rotavirus vaccines globally, there has been a significant for reduction in RVA-associated disease burden, but this virus still caused about 128,500 deaths 64 reduction in RVA-associated disease burden, but this virus still caused about 128,500 deaths
65 in 2016 alone [3.4], with the maiority of cases occurring in low-income countries [5]. In 65 in 2016 alone [3,4], with the majority of cases occurring in low-income countries [5]. In
66 Kenya, post-vaccine introduction impact studies have reported significant reduction of 66 Kenya, post-vaccine introduction impact studies have reported significant reduction of
67 rotavirus-associated diarrhoea hospitalization in children under five years, a vaccine 67 rotavirus-associated diarrhoea hospitalization in children under five years, a vaccine
68 effectiveness of ~64% [6], and a significant increase in the positivity rate of Rotarix® 68 effectiveness of ~64% [6], and a significant increase in the positivity rate of Rotarix[®]
69 heterotypic genotypes such as G2P[4] and G3P[8] [7.8]. Similar findings were observed in 69 heterotypic genotypes such as G2P[4] and G3P[8] [7,8]. Similar findings were observed in
70 other countries that introduced the Rotarix® vaccine in their NIPs [9–18] other countries that introduced the Rotarix[®] vaccine in their NIPs [9–18]

71 Whole genome analysis of RVA can reveal the transmission and evolutionary history of
72 circulating strains, including emerging mutations, and the origins and genetic diversity of the 72 circulating strains, including emerging mutations, and the origins and genetic diversity of the
73 strains circulating in a particular region [19]. The rotavirus G2P[4] genotype is known to 73 strains circulating in a particular region [19]. The rotavirus G2P[4] genotype is known to
74 nossess a DS-1 like genomic constellation (G2-P[41-I2-R2-C2-M2-A2-N2-T2-F2-H2) [20]. 74 possess a DS-1 like genomic constellation (G2-P[4]-I2-R2-C2-M2-A2-N2-T2-E2-H2) [20].
75 G2P[4] strains are believed to have undergone genetic evolution in a stepwise pattern [21]. 75 G2P[4] strains are believed to have undergone genetic evolution in a stepwise pattern [21].
76 This is from lineage I to IVa in the NSP5, NSP1, VP2, VP4, and VP7 genome segments, and 76 This is from lineage I to IVa in the NSP5, NSP1, VP2, VP4, and VP7 genome segments, and
77 from lineage I to V in the VP1, VP3, VP6, NSP2, NSP3, and NSP4 genome segments, with 77 from lineage I to V in the VP1, VP3, VP6, NSP2, NSP3, and NSP4 genome segments, with
78 some of the strains undergoing intragenotype reassortments in the VP7. VP3, and NSP4 78 some of the strains undergoing intragenotype reassortments in the VP7, VP3, and NSP4
79 seenes after 2004 giving rise to emergent lineages of V in the VP7 segment, lineages VI and 79 genes after 2004 giving rise to emergent lineages of V in the VP7 segment, lineages VI and
80 VII in the VP3 gene, and VI, VII, VIII, IX and X lineages in the NSP4 gene [21–23]. The 80 VII in the VP3 gene, and VI, VII, VIII, IX and X lineages in the NSP4 gene [21–23]. The G2P[4] lineages circulating in Kenya are unknown. ⁸¹G2P[4] lineages circulating in Kenya are unknown.

82 Characterization of South African G2P[4] strains, through comparison of strains
83 occurring during pre-and post-introduction of Rotarix® vaccine. revealed sub-lineage shifts 83 occurring during pre-and post-introduction of Rotarix® vaccine, revealed sub-lineage shifts
84 from G2 sub-lineage IVa-1 to G2 IVa-3, and PI41 sub-lineage IVa to PI41 IVb, and these 84 from G2 sub-lineage IVa-1 to G2 IVa-3, and P[4] sub-lineage IVa to P[4] IVb, and these
85 shifts in genetic evolution were attributed to arise due to natural fluctuations and not as a 85 shifts in genetic evolution were attributed to arise due to natural fluctuations and not as a
86 result of vaccine pressure [241. Similarly, G2P[41 whole genome analysis in Ghana [221. 86 result of vaccine pressure [24]. Similarly, G2P[4] whole genome analysis in Ghana [22],
87 Australia [25.26]. South Korea [11]. Bangladesh [27]. and Brazil [28] showed that 87 Australia [25,26], South Korea [11], Bangladesh [27], and Brazil [28] showed that
88 implementation of Rotarix® vaccination does not influence genetic diversity of the 88 implementation of Rotarix® vaccination does not influence genetic diversity of the
89 circulating G2PI41 strains and common amino acid replacements in the VP7 antigenic 89 circulating G2P[4] strains and common amino acid replacements in the VP7 antigenic
90 epitopes including A87T, D96N, S213D were reported, irrespective of the vaccination period. epitopes including A87T, D96N, S213D were reported, irrespective of the vaccination period.

91 The main goal of this study was to conduct whole genome analysis of the G2P[4]
92 genotypes circulating in Kilifi County, Kenya, to determine whether introduction of Rotarix® 92 genotypes circulating in Kilifi County, Kenya, to determine whether introduction of Rotarix®
93 vaccine in Kenya's NIP impacts on the genetic diversity of the circulating G2P[4] viral 93 vaccine in Kenya's NIP impacts on the genetic diversity of the circulating G2P[4] viral
94 populations. Data from this study were compared with contemporaneous global RVA strains 94 populations. Data from this study were compared with contemporaneous global RVA strains
95 to establish the phylogenetic context and potential origin of the Kenva's pre- and post-95 to establish the phylogenetic context and potential origin of the Kenya's pre- and post-
96 vaccination rotavirus G2P[4] strains. vaccination rotavirus G2P[4] strains.

97 MATERIALS AND METHODS

⁹⁸*Ethical approval*

99 We collected samples from children to screen for and determine the genetic diversity of
100 rotavirus group A (RVA) viral populations. The study was conducted with strict adherence to 100 rotavirus group A (RVA) viral populations. The study was conducted with strict adherence to
101 the study protocols approved by the Scientific and Ethics Review Unit (REF: #3049 and 101 the study protocols approved by the Scientific and Ethics Review Unit (REF: #3049 and 102 #2861) at the Kenva Medical Research Institute, KEMRI, Nairobi, Kenva, Parents and ¹⁰²#2861) at the Kenya Medical Research Institute, KEMRI, Nairobi, Kenya. Parents and 103 guardians of the eligible children were provided with sufficient information about the
104 research study to allow each individual to make informed and independent decisions for their 104 research study to allow each individual to make informed and independent decisions for their
105 children to be enrolled in the study. Sample collection proceeded after obtaining written 105 children to be enrolled in the study. Sample collection proceeded after obtaining written
106 informed consent from the parents and guardians. informed consent from the parents and guardians.

¹⁰⁷*Study participants*

108 The study was based at Kilifi County Hospital (KCH), a referral health facility that mainly
109 serves the people of Kilifi County located in the North Coast of Kenya [29]. Stool samples 109 serves the people of Kilifi County located in the North Coast of Kenya [29]. Stool samples
110 were obtained from children, aged below 13 years, who presented with diarrhoea as one of 110 were obtained from children, aged below 13 years, who presented with diarrhoea as one of
111 the illness symptoms and were admitted at KCH [6.30]. Diarrhoea was defined as passing of 111 the illness symptoms and were admitted at KCH [6,30]. Diarrhoea was defined as passing of watery stool at least three times in the last 24 hours. watery stool at least three times in the last 24 hours.

113 The stool samples were screened to detect RVA by using ELISA kit (ProSPectTM; Oxoid,
114 Basingstoke UK). All the RVA positive samples were initially genotyped by partial segment 114 Basingstoke UK). All the RVA positive samples were initially genotyped by partial segment
115 sequencing approach [7]. VP7 and VP4 genes were sequenced, and G and P genotypes 115 sequencing approach [7]. VP7 and VP4 genes were sequenced, and G and P genotypes
116 inferred using the Virus Pathogen Resource (VIPR) tool for RVA [31]. Those classified as 116 inferred using the Virus Pathogen Resource (VIPR) tool for RVA [31]. Those classified as
117 G2P[4] based on the outer capsid proteins were selected for this study (Fig. 1) [7]. $G2P[4]$ based on the outer capsid proteins were selected for this study (Fig. 1) [7].

¹¹⁸*RNA extraction and processing*

119 The samples collected in the pre-vaccine period (January 2012 – June 2014) were
120 sequenced using agnostic whole genome sequencing method [32], while the post-vaccine sequenced using agnostic whole genome sequencing method [32], while the post-vaccine

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2022.10.21.22281210;](https://doi.org/10.1101/2022.10.21.22281210) this version posted October 24, 2022. The copyright holder for this preprint

121 samples (July 2014 – December 2018) were sequenced using an amplicon-based whole
122 genome sequencing approach [33,34]. 122 genome sequencing approach [33,34].
123 Processing of pre-vaccine sample

Processing of pre-vaccine samples was done by centrifugation of 110 μL of stool
124 suspension in PBS (phosphate buffered saline) for 10 minutes at 10.000 × *p*. Next, 2 U/μl of 124 suspension in PBS (phosphate buffered saline) for 10 minutes at $10,000 \times g$. Next, 2 U/µl of 125 TURBO DNase (#AM2238: Life Technologies. Carlsbad. USA) were added to degrade non-125 TURBO DNase (#AM2238; Life Technologies, Carlsbad, USA) were added to degrade non-
126 encapsulated DNA. Nucleic acid extraction was performed according to the Boom method 126 encapsulated DNA. Nucleic acid extraction was performed according to the Boom method
127 [35]. First strand cDNA was synthesized using the SuperScript III Reverse Transcriptase Kit 127 [35]. First strand cDNA was synthesized using the SuperScript III Reverse Transcriptase Kit
128 (#18064014: Life Technologies, Carlsbad, USA) with non-ribosomal random hexamer 128 (#18064014; Life Technologies, Carlsbad, USA) with non-ribosomal random hexamer
129 primers [36]. Second strand cDNA was synthesized using 5U of Klenow fragment $3' - 5'$ 129 primers [36]. Second strand cDNA was synthesized using 5U of Klenow fragment $3' - 5'$
130 exo- (#M0212S: New England Biolabs. Inswich. USA). 130 exo- (#M0212S; New England Biolabs, Ipswich, USA).
131 Processing of post-vaccine introduction samples was

131 Processing of post-vaccine introduction samples was done by subjecting 200 mg of stool
132 specimens to bead beating [37], followed by nucleic acid extraction using the OIA amp Fast 132 specimens to bead beating [37], followed by nucleic acid extraction using the QIAamp Fast
133 DNA Stool Mini kit (#51604: Oiagen, Manchester, UK) following the manufacturer's 133 DNA Stool Mini kit (#51604; Qiagen, Manchester, UK) following the manufacturer's
134 instructions. Reverse Transcription-PCR (RT-PCR) was performed using the SuperScript IV 134 instructions. Reverse Transcription-PCR (RT-PCR) was performed using the SuperScript IV
135 One-Step RT-PCR System (#2594025, Thermo Fisher Scientific, Waltham, USA) following 135 One-Step RT-PCR System (#2594025, Thermo Fisher Scientific, Waltham, USA) following
136 the manufacturer's instructions. The published primers used in our study to conduct RT-PCR 136 the manufacturer's instructions. The published primers used in our study to conduct RT-PCR
137 assays were adopted from earlier studies (Table S1) [33.341. The PCR conditions for the non-137 assays were adopted from earlier studies (Table S1) [33,34]. The PCR conditions for the non-
138 structural gene segments (NSP1, NSP2, NSP3, NSP4, and NSP5) consisted of 40 cvcles of 138 structural gene segments (NSP1, NSP2, NSP3, NSP4, and NSP5) consisted of 40 cycles of
139 thermocycling (30 seconds at 90° C, one minute at 55° C, and four minutes at 68° C), whereas 139 thermocycling (30 seconds at 90° C, one minute at 55°C, and four minutes at 68°C), whereas
140 amplification of structural gene segments (VP1, VP2, VP3, VP4, VP6, and VP7) included 40 140 amplification of structural gene segments (VP1, VP2, VP3, VP4, VP6, and VP7) included 40
141 cycles of thermocycling (90°C for 30 seconds, 61°C for one minute and 68°C for six 141 cycles of thermocycling (90°C for 30 seconds, 61°C for one minute and 68°C for six
142 minutes), and included a final extension at 72°C for four minutes. PCR amplicons were 142 minutes), and included a final extension at 72° C for four minutes. PCR amplicons were
143 resolved under a 2% agarose gel stained with RedSafe (iNtRON Biotechnology, Inc) for 143 resolved under a 2% agarose gel stained with RedSafe (iNtRON Biotechnology, Inc) for
144 visualization of DNA bands. PCR products were purified using Exonuclease I (#EN0581; 144 visualization of DNA bands. PCR products were purified using Exonuclease I (#EN0581;
145 Thermo Fisher Scientific, Waltham, USA) as described by the manufacturer and pooled for 145 Thermo Fisher Scientific, Waltham, USA) as described by the manufacturer and pooled for
146 each sample. each sample.

¹⁴⁷*Next generation sequencing*

148 Preparation of standard Illumina libraries for pre-vaccine samples was performed
149 according to the published protocol [32]. Briefly, the double-stranded cDNA for each sample 149 according to the published protocol [32]. Briefly, the double-stranded cDNA for each sample
150 was sheared to obtain $400 - 500$ nucleotide fragments. Each sample was then indexed 150 was sheared to obtain $400 - 500$ nucleotide fragments. Each sample was then indexed
151 separately to unique adapters and multiplexed at 95 samples and then sequenced on a HiSeq 151 separately to unique adapters and multiplexed at 95 samples and then sequenced on a HiSeq
152 blatform to generate about 1.5 million 250bp paired end reads per sample. platform to generate about 1.5 million 250bp paired end reads per sample.

153 For the post-vaccine samples was done by purifying the pooled amplicons for each sample
154 using the Agencourt AMPure XP Kit (#A63881; Beckman Coulter, USA) as described by the 154 using the Agencourt AMPure XP Kit (#A63881; Beckman Coulter, USA) as described by the
155 manufacturer. Library preparation was performed using the Illumina DNA flex (#20025519. 155 manufacturer. Library preparation was performed using the Illumina DNA flex (#20025519,
156 Illumina. San Diego, USA) as per the manufacturer's specifications. Briefly, bead-linked 156 Illumina, San Diego, USA) as per the manufacturer's specifications. Briefly, bead-linked
157 transposomes were used to tagment the DNA. followed by addition of adapters to the DNA 157 transposomes were used to tagment the DNA, followed by addition of adapters to the DNA
158 fragments using a limited PCR program. The adapter-linked DNA was cleaned using the 158 fragments using a limited PCR program. The adapter-linked DNA was cleaned using the
159 tagment wash buffer. After that, the purified tagmented DNA was amplified via a limited-159 tagment wash buffer. After that, the purified tagmented DNA was amplified via a limited-
160 cvcle PCR program that adds the i7. i5 adapters and sequences required for cluster generation 160 cycle PCR program that adds the i7, i5 adapters and sequences required for cluster generation
161 during sequencing. Next, the amplified libraries were purified using a double-sided bead 161 during sequencing. Next, the amplified libraries were purified using a double-sided bead
162 purification method. Subsequently, each DNA library was quantitated, and correct insert sizes 162 purification method. Subsequently, each DNA library was quantitated, and correct insert sizes
163 confirmed on an Agilent 2100 Bioanalyzer using the Agilent high sensitivity DNA kit 163 confirmed on an Agilent 2100 Bioanalyzer using the Agilent high sensitivity DNA kit
164 (#5067: Agilent Santa Clara, USA). The DNA libraries were quantified on the Oubit 164 (#5067; Agilent, Santa Clara, USA). The DNA libraries were quantified on the Qubit 165 fluorimeter 2.0 using the Oubit dsDNA HS Assay kit (#032851. Life Technologies, Thermo 165 fluorimeter 2.0 using the Qubit dsDNA HS Assay kit (#Q32851, Life Technologies, Thermo
166 Fisher Scientific. Waltham. USA). normalized, and pooled at equimolar concentrations. 166 Fisher Scientific, Waltham, USA), normalized, and pooled at equimolar concentrations.
167 Pooled DNA libraries were denatured and sequenced on the Illumina MiSeq platform 167 Pooled DNA libraries were denatured and sequenced on the Illumina MiSeq platform
168 (Illumina San Diego, USA) to generate 150 paired end reads. ¹⁶⁸(Illumina, San Diego, USA) to generate 150 paired end reads.

¹⁶⁹*Genome assembly*

170 Quality trimming of Illumina FASTQ reads was done using Trimmomatic (Phred score
171 > 30) with the following flags "ILLUMINACLIP: adapters file: 2:30:10 LEADING:3 171 > 30) with the following flags "ILLUMINACLIP: adapters_file: 2:30:10 LEADING:3
172 TRAILING:3 SLIDINGWINDOW: 4:15 MINLEN:36" to remove adapters and low-quality 172 TRAILING:3 SLIDINGWINDOW: 4:15 MINLEN:36" to remove adapters and low-quality
173 bases [38]. De-Novo assembly of the quality trimmed reads was done using Spades with the 173 bases [38]. De-Novo assembly of the quality trimmed reads was done using Spades with the
174 following flags "-k 99.127 --careful" [39]. For the pre-vaccine sequences, RVA-specific 174 following flags "-k 99,127 --careful" [39]. For the pre-vaccine sequences, RVA-specific
175 contigs were identified using USEARCH [40] and a SLIM algorithm [41]. Partial and 175 contigs were identified using USEARCH [40] and a SLIM algorithm [41]. Partial and
176 overlapping contigs were joined using Sequencher [42] to obtain full-length sequences. For 176 overlapping contigs were joined using Sequencher [42] to obtain full-length sequences. For
177 the post-vaccine sequences. Ouast was used to check the quality of the contigs [43]. Next. 177 the post-vaccine sequences, Quast was used to check the quality of the contigs [43]. Next,
178 artemis was emploved to determine the ORFs of each RVA segment [44]. Then. genotyping 178 artemis was employed to determine the ORFs of each RVA segment [44]. Then, genotyping
179 of the assembled pre- and post-vaccine sequences was done using the Virus Pathogen 179 of the assembled pre- and post-vaccine sequences was done using the Virus Pathogen
180 Resource tool for RVA [31]. The nucleotide sequences generated in this study have been 180 Resource tool for RVA [31]. The nucleotide sequences generated in this study have been
181 deposited into GenBank under accession numbers MZ093788 to MZ097268 and OP677569 181 deposited into GenBank under accession numbers MZ093788 to MZ097268 and OP677569
182 to OP677754 (Table S2). to OP677754 (Table S2).

¹⁸³*Global sequences collection and processing*

184 All available G2P[4] sequences irrespective of the sequence length and their
185 corresponding metadata, including vear of collection and location were downloaded from the 185 corresponding metadata, including year of collection and location were downloaded from the
186 Virus Pathogen Resource of RVA [31]. Records missing metadata were manually searched ¹⁸⁶Virus Pathogen Resource of RVA [31]. Records missing metadata were manually searched

187 and any information, including location and collection year, that could be found in the
188 primary publications was included in the respective sequence data. The sequences were 188 primary publications was included in the respective sequence data. The sequences were
189 subset to obtain datasets of each genome segment. The datasets of all the genome segments 189 subset to obtain datasets of each genome segment. The datasets of all the genome segments
190 were filtered to only include samples with all the 11 segments. For all the 11 segments, more 190 were filtered to only include samples with all the 11 segments. For all the 11 segments, more
191 that 80 % of the coding sequence (CDS) region was considered for analysis. Overall, 350 191 that 80 % of the coding sequence (CDS) region was considered for analysis. Overall, 350
192 global sequences for each segment met the inclusion criteria for phylogenetic analyses (Table 192 global sequences for each segment met the inclusion criteria for phylogenetic analyses (Table 193 S2). S2).

¹⁹⁴*Phylogenetic analysis*

195 The global dataset was combined with the sequences of this study for each genome
196 segment and aligned using MAFFT (v7.487) with the command "mafft --auto --reorder --196 segment and aligned using MAFFT (v7.487) with the command "mafft --auto --reorder --
197 preservecase input file.fasta > output file.fasta" [45]. Maximum likelihood phylogenetic 197 preservecase input_file.fasta > output_file.fasta" [45]. Maximum likelihood phylogenetic
198 trees were reconstructed using IOTREE2 (v 2.1.3) [46] using the best model selection [47] 198 trees were reconstructed using IQTREE2 (v2.1.3) [46] using the best model selection [47] and 1000 bootstrap replication settings [48]. The ML trees were linked to the respective 199 and 1000 bootstrap replication settings [48]. The ML trees were linked to the respective
200 metadata in R v4.1.0 and the "ggTree" R package used to plot and visualize the trees [45]. 200 metadata in R v4.1.0 and the "ggTree" R package used to plot and visualize the trees [45].
201 For lineage designation, sequences of previously described lineages for each segment [21–23] 201 For lineage designation, sequences of previously described lineages for each segment [21–23]
202 were utilized as the references (Table S2). were utilized as the references (Table S2).

²⁰³*Statistical analyses*

204 All statistical analyses were carried out using Stata v13.1 [49]. Chi-square test was used to
205 compare among groups, with P< 0.05 indicating statistical significance. compare among groups, with $P < 0.05$ indicating statistical significance.

206 RESULTS
207 *Baseline ch*

²⁰⁷*Baseline characteristics of the study participants*

208 Peaks of rotavirus A (RVA) infections coincided with cases of diarrhoea during the study
209 period between May and September (Fig. 1). However, sample collection was majorly 209 period between May and September (Fig. 1). However, sample collection was majorly
210 disrupted in 2016 and 2017 by strikes of health care providers (Fig. 1) [6]. One huge peak of 210 disrupted in 2016 and 2017 by strikes of health care providers (Fig. 1) [6]. One huge peak of
211 G2PI41 infections was observed between June and November 2016 (post-vaccine) and a 211 G2P[4] infections was observed between June and November 2016 (post-vaccine) and a
212 small one documented between May and September 2012 (pre-vaccine) (Fig. 1). 212 small one documented between May and September 2012 (pre-vaccine) (Fig. 1).
213 No significant difference was reported in age, age groups, gender, and vacci

213 No significant difference was reported in age, age groups, gender, and vaccination status
214 between the cases infected with G2P[4] genotypes and the non-G2P[4] genotypes (P>0.05) 214 between the cases infected with G2P[4] genotypes and the non-G2P[4] genotypes (P>0.05)
215 (Table 1). G2P[4] genotypes were detected in 87 samples (20.3%), of which 63 (14.7%) were 215 (Table 1). G2P[4] genotypes were detected in 87 samples (20.3%), of which 63 (14.7%) were
216 successfully full-genome sequenced (Table 1). Of the sequenced samples, 13 (20.6%) were 216 successfully full-genome sequenced (Table 1). Of the sequenced samples, 13 (20.6%) were
217 from children who received two doses of the Rotarix® vaccine (Table 1). from children who received two doses of the Rotarix[®] vaccine (Table 1).

²¹⁸*Genome constellations*

219 To determine the genetic diversity in the Kilifi G2P[4] strains and their genetic relatedness
220 with global strains, near full-genome sequences (>80% genome coverage) of 63 Kilifi 220 with global strains, near full-genome sequences ($>80\%$ genome coverage) of 63 Kilifi
221 samples were sequenced from the pre- ($n=33$) and the post- ($n=30$) vaccine periods (Table 221 samples were sequenced from the pre- $(n=33)$ and the post- $(n=30)$ vaccine periods (Table 222 S2). Using the Virus Pathogen Resource (VIPR) for RVA genotype determination [31]. all 222 S2). Using the Virus Pathogen Resource (VIPR) for RVA genotype determination [31], all
223 the 63 sequences were classified as G2-P[4]-I2-R2-C2-M1-A2-N2-T2-E2-H1 genotype (DS-223 the 63 sequences were classified as $G2-P[4]-I2-R2-C2-M1-A2-N2-T2-E2-H1$ genotype (DS-
224 1-like typical genome constellation) as shown in Table S3. 1-like typical genome constellation) as shown in Table S3.

²²⁵*Phylogenetic and sequence analysis*

226 To gain insights into the genetic diversity of the study G2P[4] strains in the global context,
227 genetic distance-resolved phylogenetic trees were constructed for all the 11 gene segments 227 genetic distance-resolved phylogenetic trees were constructed for all the 11 gene segments
228 (Fig. 2 & Fig. S1). Sequence identity matrices of the study G2P[4] strains exhibited high 228 (Fig. 2 & Fig. S1). Sequence identity matrices of the study G2P[4] strains exhibited high
229 nucleotide sequence similarities $(93 - 100\%)$ in the NSP1, NSP2, NSP3, NSP5, VP1, VP2, 229 nucleotide sequence similarities $(93 - 100\%)$ in the NSP1, NSP2, NSP3, NSP5, VP1, VP2,
230 VP4, VP6, and VP7 genome segments, and low to high nucleotide sequence similarity $(85 -$ 230 VP4, VP6, and VP7 genome segments, and low to high nucleotide sequence similarity $(85 - 231 - 100\%)$ in the VP3 and NSP4 genes (Table 2). 100%) in the VP3 and NSP4 genes (Table 2).

²³²*Analysis of the VP7 gene*

233 The VP7 gene is highly variable and encodes the humoral immune response glycoprotein
234 [50]. The VP7 genetic distance-resolved phylogenetic tree showed that the Kilifi sequences 234 [50]. The VP7 genetic distance-resolved phylogenetic tree showed that the Kilifi sequences
235 formed three clusters: a monophyletic cluster, a minor monophyletic cluster, and a singleton 235 formed three clusters: a monophyletic cluster, a minor monophyletic cluster, and a singleton
236 (Fig. 2). Within the maior cluster, the Kilifi strains separated by vaccination period, with one 236 (Fig. 2). Within the major cluster, the Kilifi strains separated by vaccination period, with one
237 subcluster consisting of strains circulating two vears after Rotarix® vaccine introduction and 237 subcluster consisting of strains circulating two years after Rotarix® vaccine introduction and
238 were interspersed with three strains isolated from children admitted to Kenvatta National 238 were interspersed with three strains isolated from children admitted to Kenyatta National
239 Hospital (KNH). Kenya in 2017 (Fig. 2). These sequences shared two non-synonymous 239 Hospital (KNH), Kenya in 2017 (Fig. 2). These sequences shared two non-synonymous
240 amino acid substitutions (S72G, S75L) with respect to the pre-vaccine strains (Table S4). The 240 amino acid substitutions (S72G, S75L) with respect to the pre-vaccine strains (Table S4). The
241 second subcluster mainly consisted of strains circulating in the pre-vaccine period and two 241 second subcluster mainly consisted of strains circulating in the pre-vaccine period and two
242 strains that circulated in July 2014, i.e., early post-vaccine period (Fig. 2). The sequences in 242 strains that circulated in July 2014, i.e., early post-vaccine period (Fig. 2). The sequences in
243 the minor monophyletic cluster consisted of five Kilifi strains collected in 2012, while the 243 the minor monophyletic cluster consisted of five Kilifi strains collected in 2012, while the
244 singleton Kilifi strain (KLF1033/2018) clustered with three strains detected in Mozambique 244 singleton Kilifi strain (KLF1033/2018) clustered with three strains detected in Mozambique
245 in 2013 (Fig. 2). 245 in 2013 (Fig. 2).
246 With regards

246 With regards to the VP7 lineages, the Kilifi G2 strains were classified into lineage IV and
247 further classified into sub-lineage IVa-1 and IVa-3 (Fig. 2). In 2012, sub-lineages IVa-1 and 247 further classified into sub-lineage IVa-1 and IVa-3 (Fig. 2). In 2012, sub-lineages IVa-1 and 248 IVa-3 sequences co-circulated in Kilifi, while in the global context sub-lineages IVa-1. IVa-3 248 IVa-3 sequences co-circulated in Kilifi, while in the global context sub-lineages IVa-1, IVa-3
249 and IV non-a co-circulated (Fig. 3A). However, IVa-1 strains in Kilifi were replaced with 249 and IV non-a co-circulated (Fig. 3A). However, IVa-1 strains in Kilifi were replaced with
250 sub-lineage IVa-3 strains in 2013 that dominated until 2018 (Fig. 3A), unlike in the global ²⁵⁰sub-lineage IVa-3 strains in 2013 that dominated until 2018 (Fig. 3A), unlike in the global

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2022.10.21.22281210;](https://doi.org/10.1101/2022.10.21.22281210) this version posted October 24, 2022. The copyright holder for this preprint

251 context where sub-lineages IVa-1, IVa-3 and V co-circulated in 2013, sub-lineage IVa-1
252 predominantly circulated in 2014, IVa-1 and V co-circulated in 2015, and IVa-3 re-emerged

252 predominantly circulated in 2014, IVa-1 and V co-circulated in 2015, and IVa-3 re-emerged
253 in 2016 replacing lineage V and co-circulated with sub-lineage IVa-1 until 2018 (Fig. 3A).

253 in 2016 replacing lineage V and co-circulated with sub-lineage IVa-1 until 2018 (Fig. 3A).
254 No lineage shift was observed pre- and post-vaccine introduction.

No lineage shift was observed pre- and post-vaccine introduction.

²⁵⁵*Analysis of the VP4 gene*

256 The VP4 gene is highly variable and encodes a highly immunogenic protease sensitive
257 protein involved in receptor binding and cell penetration [50]. In the VP4 phylogenetic tree. 257 protein involved in receptor binding and cell penetration [50]. In the VP4 phylogenetic tree,
258 the PI41 Kilifi sequences formed clusters $(n>2)$ mainly based on the vaccination period 258 the P[4] Kilifi sequences formed clusters $(n>2)$ mainly based on the vaccination period
259 separated from global sequences (Fig. 2). However, two Kilifi sequences formed singletons. 259 separated from global sequences (Fig. 2). However, two Kilifi sequences formed singletons,
260 with the KLF1033/2018 strain clustering with a sequence isolated from a child admitted to 260 with the KLF1033/2018 strain clustering with a sequence isolated from a child admitted to
261 KNH, while the KLF0616/2012 strain was interspersed with sequences from Mozambique 261 KNH, while the KLF0616/2012 strain was interspersed with sequences from Mozambique
262 (Fig. 2). A major cluster of Kilifi sequences further sub-clustered based on the vaccination 262 (Fig. 2). A major cluster of Kilifi sequences further sub-clustered based on the vaccination
263 period, with the post-vaccine sequences interspersing with Kenvan sequences isolated from 263 period, with the post-vaccine sequences interspersing with Kenyan sequences isolated from
264 children admitted to KNH (Fig. 2). In addition. Kilifi strains collected in 2014 and some 2012 264 children admitted to KNH (Fig. 2). In addition, Kilifi strains collected in 2014 and some 2012
265 strains formed two distinct clades, clustering separately from global sequences (Fig. 2). 265 strains formed two distinct clades, clustering separately from global sequences (Fig. 2).
266 During the study period, G2 lineages II and IVa strains circulated in Kilifi, with linear

266 During the study period, G2 lineages II and IVa strains circulated in Kilifi, with lineages II
267 and IV co-circulating in 2012, consistent with the global context (Fig. 3B). From 2013 to 267 and IV co-circulating in 2012, consistent with the global context (Fig. 3B). From 2013 to
268 2018, sub-lineage IVa predominantly circulated in Kilifi similar the global context (Fig. 3B). 268 2018, sub-lineage IVa predominantly circulated in Kilifi similar the global context (Fig. 3B).
269 However, in the global context, few lineage II strains co-circulated with IVa strains in 2017 269 However, in the global context, few lineage II strains co-circulated with IVa strains in 2017
270 (Fig. 3B). No lineage shift was observed pre- and post-vaccine introduction (Fig. 2). $(Fig. 3B)$. No lineage shift was observed pre- and post-vaccine introduction $(Fig 2)$.

²⁷¹*Analysis of the backbone genome segments*

272 The backbone genome segments of the Kilifi G2P[4] strains (VP6, VP1-VP3, and NSP1-
273 NSP5) formed up to four clusters on the global phylogenetic trees (Fig.S1). In the VP6, VP1, 273 NSP5) formed up to four clusters on the global phylogenetic trees (Fig.S1). In the VP6, VP1,
274 VP2, VP3, NSP1, and NSP2 genes, maiority of the Kilifi sequences formed one maior cluster 274 VP2, VP3, NSP1, and NSP2 genes, majority of the Kilifi sequences formed one major cluster
275 which further separated into two sub-clusters of only pre- and post-vaccine sequences (Fig. 275 which further separated into two sub-clusters of only pre- and post-vaccine sequences (Fig. 276 S1). The post-vaccine strains in these genes clustered closely with 2017 sequences from 276 S1). The post-vaccine strains in these genes clustered closely with 2017 sequences from
277 KNH. Kenva (Fig.S1). In addition, the Kilifi 2014 sequences in the VP6, VP3, NSP1, and 277 KNH, Kenya (Fig.S1). In addition, the Kilifi 2014 sequences in the VP6, VP3, NSP1, and
278 NSP2 segments exhibited a different clustering pattern of a further minor sub-cluster 278 NSP2 segments exhibited a different clustering pattern of a further minor sub-cluster
279 irrespective of the vaccination period, consistent with the VP4 gene (Fig. S1). Four post-279 irrespective of the vaccination period, consistent with the VP4 gene (Fig. S1). Four post-
280 vaccine sequences were interspersed with the pre-vaccine sequences in the NSP4 gene and a 280 vaccine sequences were interspersed with the pre-vaccine sequences in the NSP4 gene and a
281 singleton of post-vaccine sequence clustered with pre-vaccine sequences in the NSP3 gene 281 singleton of post-vaccine sequence clustered with pre-vaccine sequences in the NSP3 gene
282 (Fig. S1). The NSP5 post-vaccine sequences formed one cluster, while the pre-vaccine ²⁸²(Fig. S1). The NSP5 post-vaccine sequences formed one cluster, while the pre-vaccine

283 sequences exhibited a different clustering pattern consisting of three distinct clusters (n≥2)
284 and three singletons (KLF0601/2012 was interspersed with a sequence from KNH. 284 and three singletons (KLF0601/2012 was interspersed with a sequence from KNH,
285 KLF1066/2014 and KLF0722/2014) (Fig. S1). A minor cluster consisting of five Kilifi pre-285 KLF1066/2014 and KLF0722/2014) (Fig. S1). A minor cluster consisting of five Kilifi pre-
286 vaccine strains (KLF0550/2012, KLF0551/2012, KLF0553/2012, KLF0558/2012, and 286 vaccine strains (KLF0550/2012, KLF0551/2012, KLF0553/2012, KLF0558/2012, and
287 KLF1064/2012) separate from global sequences was observed in the VP1, VP2, VP3, NSP2. 287 KLF1064/2012) separate from global sequences was observed in the VP1, VP2, VP3, NSP2,
288 NSP4, and NSP5 genes: however, interspersed with sequences that circulated between 2012 288 NSP4, and NSP5 genes; however, interspersed with sequences that circulated between 2012
289 and 2017 in Japan. Hungary. Australia, and Belgium in the NSP3 gene and further formed 289 and 2017 in Japan, Hungary, Australia, and Belgium in the NSP3 gene and further formed
290 two sub-clades in the VP6 gene (Fig. S1). In addition, a minor cluster of Kilifi pre-vaccine 290 two sub-clades in the VP6 gene (Fig. S1). In addition, a minor cluster of Kilifi pre-vaccine
291 sequences (KLF0640/2013, KLF0673/2013, and KLF0657/2013) interspersed with sequences 291 sequences (KLF0640/2013, KLF0673/2013, and KLF0657/2013) interspersed with sequences
292 from Malawi was observed in the VP3 gene, indicating possible importation of these strains 292 from Malawi was observed in the VP3 gene, indicating possible importation of these strains
293 (Fig. S1). Besides, a singleton of a post-vaccine sequence (KLF1033/2018) was interspersed 293 (Fig. S1). Besides, a singleton of a post-vaccine sequence (KLF1033/2018) was interspersed
294 with sequences from Mozambique that circulated in 2013 across all the backbone genes (Fig. 294 with sequences from Mozambique that circulated in 2013 across all the backbone genes (Fig. 295 S1). For the NSP5 gene, three other singletons were observed: KLF0601/2012 interspersed 295 S1). For the NSP5 gene, three other singletons were observed: KLF0601/2012 interspersed
296 with a sequence from KNH, KLF1066/2014 and KLF0722/2014 each separate from global 296 with a sequence from KNH, KLF1066/2014 and KLF0722/2014 each separate from global
297 sequences (Fig. S1). No lineage shifts were reported in the backbone genome segments (Fig. 297 sequences (Fig. S1). No lineage shifts were reported in the backbone genome segments (Fig. 298 S1). S1).

299 *Amino acid changes in the VP7 glycoprotein (G) and VP4 Protease sensitive (P) proteins*
300 The pattern of amino acid (aa) substitutions in the G and P proteins was analysed

300 The pattern of amino acid (aa) substitutions in the G and P proteins was analysed in
301 relation to the ancestral DS-1 sequence. The VP7 gene contains 7-1 (7-1a and 7-1b) and 7-2 301 relation to the ancestral DS-1 sequence. The VP7 gene contains 7-1 (7-1a and 7-1b) and 7-2
302 antigenic epitopes, which affect the ability of antibodies to neutralize virus infectivity and 302 antigenic epitopes, which affect the ability of antibodies to neutralize virus infectivity and
303 reduce vaccine effectiveness [51]. The Kilifi strains exhibited 17 aa changes relative to the 303 reduce vaccine effectiveness [51]. The Kilifi strains exhibited 17 aa changes relative to the
304 DS-1 VP7 ancestral sequence (Table S4). All the Kilifi strains had three aa mutations (D96N, 304 DS-1 VP7 ancestral sequence (Table S4). All the Kilifi strains had three aa mutations (D96N,
305 N125T, and V129M) in the 7-1a antigenic epitope with respect to the DS-1 ancestral strain 305 N125T, and V129M) in the 7-1a antigenic epitope with respect to the DS-1 ancestral strain
306 (Fig. 4 & Table S4). Furthermore, except for the 2014 sequences, the Kilifi sequences 306 (Fig. 4 & Table S4). Furthermore, except for the 2014 sequences, the Kilifi sequences
307 exhibited an A87T aa mutation in the 7-1a epitope (Table S4). Compared to the DS-1 307 exhibited an A87T aa mutation in the 7-1a epitope (Table S4). Compared to the DS-1
308 sequence, the Kilifi sub-lineage IVa-1 strains exhibited the N242 aa mutation, whereas sub-308 sequence, the Kilifi sub-lineage IVa-1 strains exhibited the N242 aa mutation, whereas sub-
309 lineage IVa-3 strains harboured the N213D aa mutation: both in the 71-b epitope. (Table S4). 309 lineage IVa-3 strains harboured the N213D aa mutation; both in the 71-b epitope. (Table S4).
310 Besides, the I44M aa change was observed in the T lymphocyte epitope $(40 - 52)$ of all the 310 Besides, the I44M aa change was observed in the T lymphocyte epitope $(40 - 52)$ of all the 311 Kilifi strains (Table S4). 311 Kilifi strains (Table S4).
312 The VP4 surface prote

312 The VP4 surface protein is cleaved into the VP8* and the VP5* domains containing the 8-
313 1 to 8-4 and 5-1 to 5-5 antigenic epitopes [52]. Analysis of the VP4 aa mutations revealed 313 1 to 8-4 and 5-1 to 5-5 antigenic epitopes [52]. Analysis of the VP4 aa mutations revealed
314 that the Kilifi strains differed only at three positions: O114P or L114P and N133S in the 8-3 that the Kilifi strains differed only at three positions; Q114P or L114P and N133S in the 8-3

315 epitope and N89D in the 8-4 epitope, relative to the DS-1 prototype sequence (Fig 4 $\&$ Table 316 S5). S5).

317 DISCUSSION
318 We investig

318 We investigated the evolutionary dynamics of G2P[4] strains sampled from children
319 admitted to Kilifi County Hospital. Coastal Kenya between 2012 and 2018. All the recovered 319 admitted to Kilifi County Hospital, Coastal Kenya between 2012 and 2018. All the recovered
320 senomes showed a typical DS-1 like constellation consistent with findings from several 320 genomes showed a typical DS-1 like constellation consistent with findings from several
321 countries using the Rotarix® vaccine in their NIPs [21.22.24.53]. 321 countries using the Rotarix® vaccine in their NIPs [21,22,24,53].
322 Separate clusters of pre- and post-vaccine sequences were observed.

Separate clusters of pre- and post-vaccine sequences were observed in the VP1-VP4, VP6,
323 VP7, NSP1, NSP2, and NSP5 segments. However, the strains sampled in July 2014 (early 323 VP7, NSP1, NSP2, and NSP5 segments. However, the strains sampled in July 2014 (early post-vaccine period) clustered with pre-vaccine strains across all the 11 gene segments in our 324 post-vaccine period) clustered with pre-vaccine strains across all the 11 gene segments in our
325 study possibly because the vaccine coverage was low and thus had no impact vet on the 325 study possibly because the vaccine coverage was low and thus had no impact yet on the
326 circulating genotypes and lineages. Unique clusters of either G2PI41 or G1IP81 strains 326 circulating genotypes and lineages. Unique clusters of either G2P[4] or G1[P8] strains
327 separated by RVA vaccine period have been reported in South Africa [24]. Rwanda [54]. separated by RVA vaccine period have been reported in South Africa [24], Rwanda [54],
328 Australia and Belgium [55], which were interpreting as reflecting natural genetic fluctuations 328 Australia and Belgium [55], which were interpreting as reflecting natural genetic fluctuations
329 rather than vaccine induced evolution. However, the study NSP4 and NSP3 genes exhibited 329 rather than vaccine induced evolution. However, the study NSP4 and NSP3 genes exhibited
330 some clusters of mixed pre- and post-vaccine sequences, indicating that in some strains the 330 some clusters of mixed pre- and post-vaccine sequences, indicating that in some strains the
331 pre-vaccine may have reassorted with post-vaccine introduction strains as similarly suspected 331 pre-vaccine may have reassorted with post-vaccine introduction strains as similarly suspected
332 in Mozambique, albeit in G1P[8] [56]. in Mozambique, albeit in G1P[8] [56].

333 Phylogenetic analyses indicated that the diversity of the Kilifi G2P[4] strains may have
334 been locally restricted both in the pre- and post-vaccine periods, since Kilifi sequences 334 been locally restricted both in the pre- and post-vaccine periods, since Kilifi sequences
335 clustered away from global sequences in all the 11 genome segments. In addition, limited 335 clustered away from global sequences in all the 11 genome segments. In addition, limited
336 sequence data from Kenva and East Africa may have contributed to this uncertainty about the 336 sequence data from Kenya and East Africa may have contributed to this uncertainty about the
337 regional context of Kilifi diversity. The Kilifi post-vaccine strains only clustered with 337 regional context of Kilifi diversity. The Kilifi post-vaccine strains only clustered with
338 Kenvan sequences sampled from children admitted to Kenvatta National Hospital in 2017. 338 Kenyan sequences sampled from children admitted to Kenyatta National Hospital in 2017,
339 further suggesting locally restricted genetic evolution. However, one sample 339 further suggesting locally restricted genetic evolution. However, one sample
340 (KLF1033/2018) consistently clustered with sequences from Mozambique and some pre-340 (KLF1033/2018) consistently clustered with sequences from Mozambique and some pre-
341 vaccine strains were interspersed with global strains for the NSP3 segment, suggestive of 341 vaccine strains were interspersed with global strains for the NSP3 segment, suggestive of
342 limited introduction from other countries. No lineage shift was observed pre- and post-342 limited introduction from other countries. No lineage shift was observed pre- and post-
343 periods in Kilifi inconsistent with findings in South Africa [24] where RVA vaccine 343 periods in Kilifi inconsistent with findings in South Africa [24] where RVA vaccine
344 introduction resulted in lineage shift. Furthermore, few G2 and P^[4] lineages were in 344 introduction resulted in lineage shift. Furthermore, few G2 and P[4] lineages were in
345 circulation within Kilifi compared with the combined global data during the study period. ³⁴⁵circulation within Kilifi compared with the combined global data during the study period.

346 This supported our hypothesis that local drivers were responsible for the diversity within the 347 Kilifi setting. Kilifi setting.

348 The Kilifi strains harbored six conserved amino acid (aa) substitutions in the VP7
349 antigenic epitopes: 7-1a and 7-1b with respect to the ancestral DS-1 G2P[4] strain. Three of 349 antigenic epitopes; 7-1a and 7-1b with respect to the ancestral DS-1 G2P[4] strain. Three of
350 these positions (A87T, D96N, and N213D) are critical for antibody binding and sequence 350 these positions (A87T, D96N, and N213D) are critical for antibody binding and sequence
351 changes here may lead to escape from host neutralizing antibodies [57]. The I44M aa change 351 changes here may lead to escape from host neutralizing antibodies [57]. The I44M aa change
352 may affect cellular immunity as this region harbors a known T lymphocyte epitope (40-52) of 352 may affect cellular immunity as this region harbors a known T lymphocyte epitope (40-52) of
353 the VP7 genes. All Kilifi strains had this change that potentially result in loss of recognition 353 the VP7 genes. All Kilifi strains had this change that potentially result in loss of recognition
354 by T cells leading to escape from host immune responses [58.59]. Three aa acid changes were 354 by T cells leading to escape from host immune responses [58,59]. Three aa acid changes were
355 observed in VP4 antigenic epitopes in 8-4 (N89D) and 8-3 (O114P or L114P and N133S) in 355 observed in VP4 antigenic epitopes in 8-4 (N89D) and 8-3 (Q114P or L114P and N133S) in
356 the Kilifi strains. These have been associated with escape of attachment of the virus to host 356 the Kilifi strains. These have been associated with escape of attachment of the virus to host
357 neutralizing monoclonal antibodies [60]. These aa substitutions were present in both pre- and 357 neutralizing monoclonal antibodies [60]. These aa substitutions were present in both pre- and
358 post-vaccine Kilifi strains, suggesting they were not brought about by vaccine use. ³⁵⁸post-vaccine Kilifi strains, suggesting they were not brought about by vaccine use.

359 This study had limitations. First, only sequences sampled from hospitalized children were
360 analysed, thus may not conclusively reflect diversity that was in circulation in the entire 360 analysed, thus may not conclusively reflect diversity that was in circulation in the entire
361 coastal Kenya population. We only analysed a few genomes across the years. Second, we 361 coastal Kenya population. We only analysed a few genomes across the years. Second, we
362 only recovered near complete genomes. Only 68% coverage was recovered in the VP4 362 only recovered near complete genomes. Only 68% coverage was recovered in the VP4
363 segment. segment.

364 In conclusion, our study reinforces the significance of genomic sequencing in monitoring
365 the effect of vaccine pressure on circulating RVA strains in Kenva. The Kilifi strains to a 365 the effect of vaccine pressure on circulating RVA strains in Kenya. The Kilifi strains to a
366 large extent clustered based on the vaccination period and were separate from the global 366 large extent clustered based on the vaccination period and were separate from the global
367 strains. Furthermore, conserved amino acid mutations were observed in the VP7 and VP4 367 strains. Furthermore, conserved amino acid mutations were observed in the VP7 and VP4
368 antigenic epitopes of the pre- and post-vaccine strains, suggesting that the Rotarix® vaccine 368 antigenic epitopes of the pre- and post-vaccine strains, suggesting that the Rotarix[®] vaccine
369 did not have a direct impact on the evolution of the circulating strains. did not have a direct impact on the evolution of the circulating strains.

370 Data availability
371 The epidemiological 371 The epidemiological data is available on the VEC dataverse ³⁷²(https://doi.org/10.7910/DVN/P4MRVF).

373 Funding information
374 This study was fund

374 This study was funded by the Wellcome Trust (102975, 203077). The authors Timothy
375 Makori, and Charles Agoti were supported by the Initiative to Develop African Research 375 Makori, and Charles Agoti were supported by the Initiative to Develop African Research
376 Leaders (IDeAL) through the DELTAS Africa Initiative (DEL-15-003). The DELTAS Africa Leaders (IDeAL) through the DELTAS Africa Initiative (DEL-15-003). The DELTAS Africa

377 Initiative is an independent funding scheme of the African Academy of Sciences (AAS)'s
378 Alliance for Accelerating Excellence in Science in Africa (AESA) and supported by the New 378 Alliance for Accelerating Excellence in Science in Africa (AESA) and supported by the New
379 Partnership for Africa's Development Planning and Coordinating Agency (NEPAD Agency) 379 Partnership for Africa's Development Planning and Coordinating Agency (NEPAD Agency)
380 with funding from the Wellcome Trust (107769/Z/10/Z) and the UK government. The views 380 with funding from the Wellcome Trust $(107769/Z/10/Z)$ and the UK government. The views
381 expressed in this publication are those of the authors and not necessarily those of AAS. 381 expressed in this publication are those of the authors and not necessarily those of AAS,
382 NEPAD Agency. Wellcome Trust or the UK government.

- 382 NEPAD Agency, Wellcome Trust or the UK government.
383
-

384 Acknowledgement
385 We thank all the

385 We thank all the study participants for their contribution of study samples, their
386 parents/guardians, members of the viral epidemiology and control research group 386 parents/guardians, members of the viral epidemiology and control research group
387 (http://virec-group.org/) and colleagues at the KEMRI Wellcome Trust Research Programme 387 (http://virec-group.org/) and colleagues at the KEMRI Wellcome Trust Research Programme
388 for their useful discussions during the preparation of the manuscript. This paper is published 388 for their useful discussions during the preparation of the manuscript. This paper is published
389 with the permission of the Director of KEMRI.

- 389 with the permission of the Director of KEMRI.
390
- 390

391 Conflicts of interest
392 The authors declare

- 392 The authors declare no conflict of interest 393
-

394 References

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2022.10.21.22281210;](https://doi.org/10.1101/2022.10.21.22281210) this version posted October 24, 2022. The copyright holder for this preprint

- 444 12. Zeller M, Rahman M, Heylen E, et al. Rotavirus incidence and genotype
445 distribution before and after national rotavirus vaccine introduction in Belgium. 445 distribution before and after national rotavirus vaccine introduction in Belgium.
446 Vaccine [Internet]. 2010 Nov 3 [cited 2022 Aug 2]:28(47):7507–13. Available 446 Vaccine [Internet]. 2010 Nov 3 [cited 2022 Aug 2];28(47):7507–13. Available
447 from: https://pubmed.ncbi.nlm.nih.gov/20851085/
- 447 from: https://pubmed.ncbi.nlm.nih.gov/20851085/
448 13. Khandoker N, Thongprachum A, Takanashi S, et a 448 13. Khandoker N, Thongprachum A, Takanashi S, et al. Molecular epidemiology of rotavirus gastroenteritis in Japan during 2014-2015: Characterization of re-449 rotavirus gastroenteritis in Japan during 2014-2015: Characterization of re-
450 emerging G2P[4] after rotavirus vaccine introduction. J Med Virol [Internet]. 450 emerging G2P[4] after rotavirus vaccine introduction. J Med Virol [Internet].
451 2018 Jun 1 [cited 2022 Aug 2];90(6):1040–6. Available from: 451 2018 Jun 1 [cited 2022 Aug 2];90(6):1040–6. Available from:
452 https://pubmed.nchi.nlm.nib.gov/29488230/ 452 https://pubmed.ncbi.nlm.nih.gov/29488230/
453 14 Carvalho-Costa EA de Assis RMS E
- 453 14. Carvalho-Costa FA, de Assis RMS, Fialho AM, et al. The evolving epidemiology of rotavirus A infection in Brazil a decade after the introduction 454 epidemiology of rotavirus A infection in Brazil a decade after the introduction
455 of universal vaccination with Rotarix®. BMC Pediatr [Internet]. 2019 Jan 31 455 of universal vaccination with Rotarix®. BMC Pediatr [Internet]. 2019 Jan 31
456 [cited 2022 Aug 2];19(1):1–10. Available from: 456 $\begin{array}{r} \text{[cited} \quad 2022 \quad \text{Aug} \quad 2];19(1):1-10. \quad \text{Available} \quad \text{from:} \end{array}$ 457 https://bmcpediatr.biomedcentral.com/articles/10.1186/s12887-019-1415-9
458 15 Degiuseppe II Stupka JA First assessment of all-cause acute diarrhoea
- 458 15. Degiuseppe JI, Stupka JA. First assessment of all-cause acute diarrhoea and rotavirus-confirmed cases following massive vaccination in Argentina. 459 rotavirus-confirmed cases following massive vaccination in Argentina.
460 Foidemiol Infect [Internet]. 2018 Nov 1 [cited 2022 Aug 21:146(15):1948. 460 Epidemiol Infect [Internet]. 2018 Nov 1 [cited 2022 Aug 2];146(15):1948.
461 Available from: /pmc/articles/PMC6452988/ 461 Available from: /pmc/articles/PMC6452988/
462 16. Simwaka JC, Mpabalwani EM, Seheri M, e
- 462 16. Simwaka JC, Mpabalwani EM, Seheri M, et al. Diversity of rotavirus strains circulating in children under five vears of age who presented with acute 463 circulating in children under five years of age who presented with acute
464 gastroenteritis before and after rotavirus vaccine introduction, University 464 gastroenteritis before and after rotavirus vaccine introduction, University
465 Teaching Hospital, Lusaka, Zambia, 2008-2015. Vaccine [Internet]. 2018 Nov 465 Teaching Hospital, Lusaka, Zambia, 2008-2015. Vaccine [Internet]. 2018 Nov
466 12 [cited 2022 Aug 2];36(47):7243–7. Available from: 466 $12 \quad \text{[cited} \quad 2022 \quad \text{Aug} \quad 2];36(47):7243-7. \quad \text{Available} \quad \text{from:}$
467 https://pubmed.nchi.nlm.nib.gov/29907481/ 467 https://pubmed.ncbi.nlm.nih.gov/29907481/
468 17 Al-Ayed MSZ Asaad AM Qureshi MA Ha
- 468 17. Al-Ayed MSZ, Asaad AM, Qureshi MA, Hawan AA. Epidemiology of group A
469 totavirus infection after the introduction of monovalent vaccine in the National 469 rotavirus infection after the introduction of monovalent vaccine in the National
470 Immunization Program of Saudi Arabia. J Med Virol [Internet]. 2017 Mar 1 470 Immunization Program of Saudi Arabia. J Med Virol [Internet]. 2017 Mar 1
471 [cited 2022 Aug 2]:89(3):429–34. Available from: 471 [cited 2022 Aug 2];89(3):429–34. Available from:
472 https://pubmed.nchi.nlm.nib.gov/27531633/ 472 https://pubmed.ncbi.nlm.nih.gov/27531633/
473 18 Than VT Jeong S. Kim W. A systematic re
- 473 18. Than VT, Jeong S, Kim W. A systematic review of genetic diversity of human
474 rotavirus circulating in South Korea. Infect Genet Evol [Internet], 2014 Dec 474 rotavirus circulating in South Korea. Infect Genet Evol [Internet]. 2014 Dec
475 [cited 2018 Mar 16];28:462–9. Available from: 475 [cited 2018 Mar 16];28:462–9. Available from:
476 http://linkingbub.elsevier.com/retrieve/pii/S1567134814003086 476 http://linkinghub.elsevier.com/retrieve/pii/S1567134814003086
477 19 Ghosh S. Kohayashi N. Whole-genomic analysis of rotavirus
- 477 19. Ghosh S, Kobayashi N. Whole-genomic analysis of rotavirus strains: Current 478 tatus and future prospects [Internet]. Vol. 6, Future Microbiology. Future 478 status and future prospects [Internet]. Vol. 6, Future Microbiology. Future 479 Medicine Ltd London, UK ; 2011 [cited 2020 Oct 26]. p. 1049–65. Available 479 Medicine Ltd London, UK ; 2011 [cited 2020 Oct 26]. p. 1049–65. Available from: www.futuremedicine.com 480 from: www.futuremedicine.com
481 20. Matthijnssens J, Ciarlet M, R
- 481 20. Matthijnssens J, Ciarlet M, Rahman M, et al. Recommendations for the classification of group A rotaviruses using all 11 genomic RNA segments. Arch 482 classification of group A rotaviruses using all 11 genomic RNA segments. Arch
483 Virol [Internet]. 2008 [cited 2018 Jan 5]:153(8):1621–9. Available from: 483 Virol [Internet]. 2008 [cited 2018 Jan 5];153(8):1621–9. Available from:
484 http://link.springer.com/10.1007/s00705-008-0155-1 484 http://link.springer.com/10.1007/s00705-008-0155-1
485 21. Doan YH, Nakagomi T, Agbemabiese CA, Naka
- 485 21. Doan YH, Nakagomi T, Agbemabiese CA, Nakagomi O. Changes in the distribution of lineage constellations of G2P[4] Rotavirus A strains detected in 486 distribution of lineage constellations of G2P[4] Rotavirus A strains detected in
487 Japan over 32 years (1980-2011). Infection, Genetics and Evolution [Internet]. 187 Japan over 32 years (1980-2011). Infection, Genetics and Evolution [Internet].
188 2015 Aug 1 [cited 2020 Oct 27]:34:423–33. Available from: 488 2015 Aug 1 [cited 2020 Oct 27];34:423–33.
489 https://pubmed.ncbi.nlm.nih.gov/26026594/ 489 https://pubmed.ncbi.nlm.nih.gov/26026594/
490 22. Agbemabiese CA, Nakagomi T, Doan YH
- 490 22. Agbemabiese CA, Nakagomi T, Doan YH, Do LP, Damanka S, Armah GE, 491 Nakagomi O. Genomic constellation and evolution of Ghanaian G2P[4] 491 Nakagomi O. Genomic constellation and evolution of Ghanaian G2P[4]
492 rotavirus strains from a global perspective. Infection. Genetics and Evolution. 492 rotavirus strains from a global perspective. Infection, Genetics and Evolution.
493 2016 Nov 1;45:122–31. 2016 Nov 1;45:122–31.

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2022.10.21.22281210;](https://doi.org/10.1101/2022.10.21.22281210) this version posted October 24, 2022. The copyright holder for this preprint

- 592 47. Subha K, Minh BQ, Wong TKF, von Haeseler A, Jermiin LS. ModelFinder:
593 Fast model selection for accurate phylogenetic estimates. Nat Methods. 2017 593 Fast model selection for accurate phylogenetic estimates. Nat Methods. 2017
594 May 30:14(6):587–9. 594 May 30;14(6):587–9.
595 48. Hoang DT, Chernon 595 48. Hoang DT, Chernomor O, Haeseler A von, Minh BQ, Vinh LS. UFBoot2:
596 Improving the Ultrafast Bootstrap Approximation. Mol Biol Evol [Internet]. 596 Improving the Ultrafast Bootstrap Approximation. Mol Biol Evol [Internet].
597 2018 Feb 1 [cited 2021 Oct 28];35(2):518. Available from: 597 2018 Feb 1 [cited 2021 Oct 28];35(2):518. Available from:
598 /pmc/articles/PMC5850222/ 598 /pmc/articles/PMC5850222/
599 19 Statistical software for data 599 49. Statistical software for data science | Stata [Internet]. [cited 2022 Oct 13].
600 Available from: https://www.stata.com/ 600 Available from: https://www.stata.com/
601 50. Liu L. Fields Virology, 6th Edition. Clin 601 50. Liu L. Fields Virology, 6th Edition. Clinical Infectious Diseases [Internet]. 2014
602 Aug 15 [cited 2022 Sep 15]:59(4):613–613. Available from: 602 Aug 15 [cited 2022 Sep 15];59(4):613–613. Available from:
603 https://academic.oup.com/cid/article/59/4/613/2895607 603 https://academic.oup.com/cid/article/59/4/613/2895607
604 605 Aoki ST, Settembre EC, Trask SD, Greenberg HB, Har 604 51. Aoki ST, Settembre EC, Trask SD, Greenberg HB, Harrison SC, Dormitzer PR.
605 Structure of rotavirus outer-layer protein VP7 bound with a neutralizing Fab. 605 Structure of rotavirus outer-layer protein VP7 bound with a neutralizing Fab.
606 Science [Internet]. 2009 Jun 6 [cited 2022 Aug 11];324(5933):1444. Available 606 Science [Internet]. 2009 Jun 6 [cited 2022 Aug 11];324(5933):1444. Available from: /pmc/articles/PMC2995306/ 607 from: /pmc/articles/PMC2995306/
608 52. Dormitzer PR. Sun ZYJ. Wagner ⁶⁰⁸52. Dormitzer PR, Sun ZYJ, Wagner G, Harrison SC. The rhesus rotavirus VP4 609 sialic acid binding domain has a galectin fold with a novel carbohydrate binding
610 site. EMBO Journal. 2002 Mar 1;21(5):885–97. 610 site. EMBO Journal. 2002 Mar 1;21(5):885–97.
611 53. Dennis AF, McDonald SM, Payne DC, et a 611 53. Dennis AF, McDonald SM, Payne DC, et al. Molecular epidemiology of contemporary G2P[4] human rotaviruses cocirculating in a single U.S. 612 contemporary G2P[4] human rotaviruses cocirculating in a single U.S.
613 community: footprints of a globally transitioning genotype. J Virol [Internet]. 613 community: footprints of a globally transitioning genotype. J Virol [Internet].
614 2014 Apr 1 [cited 2018 Mar 15];88(7):3789–801. Available from: 614 2014 Apr 1 [cited 2018 Mar 15];88(7):3789–801. Available from:
615 http://jvi.asm.org/cgi/doi/10.1128/JVI.03516-13 615 http://jvi.asm.org/cgi/doi/10.1128/JVI.03516-13
616 54. Rasebotsa S, Mwangi PN, Mogotsi MT, et a 616 54. Rasebotsa S, Mwangi PN, Mogotsi MT, et al. Whole genome and in-silico
617 analyses of G1P[8] rotavirus strains from pre- and post-vaccination periods in 617 analyses of G1P[8] rotavirus strains from pre- and post-vaccination periods in
618 Rwanda. Scientific Reports 2020 10:1 [Internet]. 2020 Aug 10 [cited 2022 Aug 618 Rwanda. Scientific Reports 2020 10:1 [Internet]. 2020 Aug 10 [cited 2022 Aug
619 15];10(1):1–22. Available from: https://www.nature.com/articles/s41598-020-619 15];10(1):1–22. Available from: https://www.nature.com/articles/s41598-020-
620 69973-1 620 69973-1
621 55. Zeller M 621 55. Zeller M, Donato C, Trovão NS, et al. Genome-Wide Evolutionary Analyses of 622 61PI81 Strains Isolated Before and After Rotavirus Vaccine Introduction. 622 G1P[8] Strains Isolated Before and After Rotavirus Vaccine Introduction.
623 Genome Biol Evol [Internet]. 2015 Sep 1 [cited 2022 Aug 15];7(9):2473–83. 623 Genome Biol Evol [Internet]. 2015 Sep 1 [cited 2022 Aug 15];7(9):2473–83.
624 Available from: https://pubmed.ncbi.nlm.nih.gov/26254487/ 624 Available from: https://pubmed.ncbi.nlm.nih.gov/26254487/
625 56. Munlela B, João ED, Donato CM, et al. Whole Genome C 625 56. Munlela B, João ED, Donato CM, et al. Whole Genome Characterization and Evolutionary Analysis of G1P[8] Rotavirus A Strains during the Pre- and Post-626 Evolutionary Analysis of G1P[8] Rotavirus A Strains during the Pre- and Post-
627 Vaccine Periods in Mozambique (2012–2017). Pathogens [Internet]. 2020 Dec 1 627 Vaccine Periods in Mozambique (2012–2017). Pathogens [Internet]. 2020 Dec 1
628 [cited 2022 Aug 191:9(12):1–19. Available from: /pmc/articles/PMC7762294/ 628 [cited 2022 Aug 19];9(12):1–19. Available from: /pmc/articles/PMC7762294/
629 57. Dyall-Smith ML, Lazdins I, Tregear GW, Holmes IH. Location of the maj 629 57. Dyall-Smith ML, Lazdins I, Tregear GW, Holmes IH. Location of the major
630 antigenic sites involved in rotavirus serotype-specific neutralization. Proc Natl 630
antigenic sites involved in rotavirus serotype-specific neutralization. Proc Natl
631 Acad Sci U S A [Internet]. 1986 [cited 2022 Jun 31:83(10):3465–8. Available 631 Acad Sci U S A [Internet]. 1986 [cited 2022 Jun 3];83(10):3465–8. Available from: https://pubmed.ncbi.nlm.nih.gov/2422651/ 632 from: https://pubmed.ncbi.nlm.nih.gov/2422651/
633 58. Morozova O v., Sashina TA, Fomina SG, 633 58. Morozova O v., Sashina TA, Fomina SG, Novikova NA. Comparative characteristics of the VP7 and VP4 antigenic epitopes of the rotaviruses 634 characteristics of the VP7 and VP4 antigenic epitopes of the rotaviruses circulating in Russia (Nizhny Novgorod) and the Rotarix and RotaTeq vaccines. 635 circulating in Russia (Nizhny Novgorod) and the Rotarix and RotaTeq vaccines.
636 Arch Virol. 2015 Jul 15:160(7):1693–703. 636 Arch Virol. 2015 Jul 15;160(7):1693–703.
637 59. Wei J, Li J, Zhang X, Tang Y, Wang J, Wi
- 637 59. Wei J, Li J, Zhang X, Tang Y, Wang J, Wu Y. A naturally processed epitope on rotavirus VP7 glycoprotein recognized by HLA-A2.1-restricted cytotoxic CD8+ 638 rotavirus VP7 glycoprotein recognized by HLA-A2.1-restricted cytotoxic CD8+
639 T cells. Viral Immunol. 2009 Jun 1:22(3):189–94. 639 T cells. Viral Immunol. 2009 Jun 1;22(3):189–94.
640 60. Monnier N, Higo-Moriguchi K, Sun Z-YJ, 1
- 640 60. Monnier N, Higo-Moriguchi K, Sun Z-YJ, Prasad BVV, Taniguchi K, 641 Dormitzer PR. High-Resolution Molecular and Antigen Structure of the VP8^{*} ⁶⁴¹Dormitzer PR. High-Resolution Molecular and Antigen Structure of the VP8*

- - -
646
- $\frac{1}{\sqrt{2}}$

647

medRxiv preprint doi: https://doi.org/10.1101/2022.10.21.22281210; this version posted October 24, 2022. The copyright holder for this preprint
(which was not certified by peer review) is the author/tunder, who has granted The copyright holder for this preprint holder for this version posted October 24, 2022. I he copyright this started in the copyright in each and \sim 2021. In each and \sim 2021. In each and \sim 2022. In the copyright of who has granted by perfact in the authorycle and has granted medRxix a license to display the prepriation in perpetuity. . [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) It is made available under a

656
657

658 658 Fig. 2: Phylogenetic reconstruction of the 63 Kilifi G2P[4] sequences against a backdrop of 659 350 global sequences for the VP7 and VP4 RVA genome segments using maximum 659 350 global sequences for the VP7 and VP4 RVA genome segments using maximum
660 likelihood (ML) methods. The Kilifi sequences are colored by the period of sample collection 660 likelihood (ML) methods. The Kilifi sequences are colored by the period of sample collection
661 (either before or after vaccine introduction in Kenya). For all the global sequences, more than 661 (either before or after vaccine introduction in Kenya). For all the global sequences, more than
662 80% of the coding sequence (CDS) region was considered for analysis. For the Kilifi 662 80% of the coding sequence (CDS) region was considered for analysis. For the Kilifi
663 sequences, >80% CDS were used for the VP7 and 68% for the VP4 segment. The study 663 sequences, >80% CDS were used for the VP7 and 68% for the VP4 segment. The study sequences classified to the lineages indicated in each phylogenetic tree. sequences classified to the lineages indicated in each phylogenetic tree.

665
666

667 667 Fig. 3: Temporal pattern of the G2 and P[4] lineages observed in Kilifi and globally. (A)
668 Temporal pattern of the Kilifi G2 lineages from 2012 to 2018 and temporal pattern of the

668 Temporal pattern of the Kilifi G2 lineages from 2012 to 2018 and temporal pattern of the global G2 lineages from 2010 to 2018. (C) Temporal pattern of the Kilifi P[4] lineages from

669 global G2 lineages from 2010 to 2018. (C) Temporal pattern of the Kilifi P[4] lineages from
670 2012 to 2018 and temporal pattern of the global P[4] lineages from 2010 to 2018.

2012 to 2018 and temporal pattern of the global P[4] lineages from 2010 to 2018.

671
672

672 673 Fig. 4: A sequence logo showing the amino changes observed in known antigenic epitopes of 674 G2 and P[4] proteins in the Kilifi G2P[4] relative to the ancestral DS-1 strain. The changes in 674 G2 and P[4] proteins in the Kilifi G2P[4] relative to the ancestral DS-1 strain. The changes in amino acids are shown in different color schemes. 675 amino acids are shown in different color schemes.
676

-
- 677
- 678
-
-
- 680
681
- 682
- 682
-
- 684
685 685
- 686
687
-
- 688 688
- 690
-
-
- 692

693 Supplementary Figure Legend
694 Fig. S1: Phylogenetic reconstru

694 Fig. S1: Phylogenetic reconstruction of the 63 Kilifi G2P[4] sequences against a backdrop of 695 350 global sequences for the VP6, VP1, VP2, VP3, NSP1, NSP2, NSP3, NSP4, and NSP5 695 350 global sequences for the VP6, VP1, VP2, VP3, NSP1, NSP2, NSP3, NSP4, and NSP5
696 RVA genome segments using maximum likelihood (ML) methods. The Kilifi sequences are 696 RVA genome segments using maximum likelihood (ML) methods. The Kilifi sequences are
697 colored by the period of sample collection (either before or after vaccine introduction in 697 colored by the period of sample collection (either before or after vaccine introduction in
698 Kenva). For the Kilifi and all the global sequences, more than 80% of the coding sequence 698 Kenya). For the Kilifi and all the global sequences, more than 80% of the coding sequence
699 (CDS) region was considered for analysis. The study sequences classified to the lineages 699 (CDS) region was considered for analysis. The study sequences classified to the lineages
700 indicated in each phylogenetic tree. indicated in each phylogenetic tree.

Table 1: Baseline demographic characteristics of the children that were rotavirus positive and those found to be G2P[4] infected during the study period (2012 to 2018)

 $\frac{1}{1}$ 1 Full vaccination implies that the participants received two doses of the Rotarix vaccine as recommended by WHO

